MA-MEIJI-SEIKA-PHARMA
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Daikichiro Kobayashi), a leading Japanese pharmaceutical company specializing in infectious diseases, vaccines, and hematology, announced today that it has established a new office in the Boston area, USA, and is initiating venture investments in the life science and healthcare fields. Through its investment activities, Meiji Seika Pharma aims to discover and develop cutting-edge therapies and contribute to solving unmet medical needs of patients worldwide, reflecting the company’s unwavering commitment to innovation and global health.
Meiji Seika Pharma was founded in 1916, started pharmaceutical business in 1946, and has grown to be a leading Japanese pharmaceutical company. The company has been at the forefront of research and development of therapeutics and vaccines for infectious diseases. In December 2023, Meiji Seika Pharma obtained the world’s first marketing approval for a self-amplifying mRNA vaccine against COVID-19 (Kostaive®). In addition to its focus on infectious diseases area, Meiji Seika Pharma is dedicated to drug discovery and development in hematology and oncology. The company has developed and launched a selective ROCK2 inhibitor (belumosudil mesilate) for the treatment of chronic GVHD, and an HDAC inhibitor (tucidinostat) for ATLL and PTCL in Japan. As a fully integrated pharmaceutical company, it has over 5,500 employees worldwide.
Meiji Seika Pharma will expand its presence in the Boston area by opening a new office and explore venture investments at the center of innovation. Located at CIC Cambridge (One Broadway, Cambridge, MA 02142), the new office will act as a strategic hub, fostering investment opportunities that align with the Meiji Seika Pharma’s current vision for growth and innovation. Meiji Seika Pharma will initiate investments in startups and venture capital firms that focus on drug discovery and innovative platform technology. The office is organized as part of Meiji Pharma USA Inc., a subsidiary of Meiji Seika Pharma.
“We are pleased to deepen our expertise in infectious diseases area as well as other focus areas,” said Mr. Daikichiro Kobayashi, President and Representative Director of Meiji Seika Pharma. “Our Boston office will facilitate collaboration with pioneering bioventures and startups, furthering our mission to develop innovative solutions such as groundbreaking therapeutics and beyond the pills.”
Meiji Seika Pharma’s challenges into these innovative approaches show its commitment to addressing critical health challenges and improving patient outcomes on a global scale. By leveraging the Boston area’s dynamic ecosystem, the company aims to accelerate its research and development efforts and bring breakthrough therapies to global market.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240808269845/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting udvider sine digitale transformationsservices i samarbejde med Digital Works Group27.9.2025 02:40:00 CEST | Pressemeddelelse
Andersen Consulting styrker sine kapaciteter inden for forretningstransformation og digital transformation gennem en samarbejdsaftale med Digital Works Group, der er kendt for at skabe komplekse forandringer og løse forretningsudfordringer gennem digitalisering, data, AI og procestransformation. Digital Works Group, der blev grundlagt i 2011, tilbyder strategisk støtte til kunder, der navigerer i komplekse kommercielle og operationelle forandringer – ofte via digital og datadrevet innovation samt banebrydende teknologier som AI og blockchain. Virksomheden er specialiseret i forretningsstrategi, konkurrenceanalyse samt digital transformation og data- og AI-transformation – med særligt fokus på kundeoplevelse, datastyring og governance, AI-integration og agil procesoptimering. Digital Works Group støtter kunder på tværs af sektorer, herunder finansielle tjenester, det offentlige, B2B, telekommunikation, detailhandel og non-profit. De guider kunderne fra planlægning til eksekvering med en
Sultan bin Ahmed Visits Al Rahma Village in Sri Lanka26.9.2025 22:21:00 CEST | Press release
His Highness Sheikh Sultan bin Ahmed Al Qasimi, Deputy Ruler of Sharjah and Chairman of the Sharjah Media Council, visited Al Rahma Women’s Village in Puttalam, Sri Lanka, a community dedicated to widows, orphans, and their families. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250926962681/en/ Sultan bin Ahmed visits Al Rahma Village in Sri Lanka (Photo: AETOSWire) His Highness toured the village, exploring its facilities. He viewed the exhibition of the village’s diverse products, which are sold and exported to neighboring villages, and visited the women’s training rooms where sewing skills are taught. He also inspected the medical center, which provides free healthcare services for women and children, and met with children in the village’s garden, designed as a recreational space for them. He inaugurated 40 new houses by cutting the ceremonial ribbon, handing them over to deserving widows. He then visited the classrooms
L&T Technology Services, Siemens Partner for AI-led Transformation in Process Engineering & Smart Manufacturing26.9.2025 10:30:00 CEST | Press release
Collaboration will unlock new possibilities in LTTS’ Sustainability segment; to deliver simulation-driven automation & AI-enabled solutions for diverse sectors L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, announced an expanded partnership with Siemens Limited, a leading technology company focused on industry, infrastructure and mobility. This collaboration aims to advance Machine & Line Simulation and IIoT Technology, setting a new benchmark for innovation within LTTS’ Sustainability segment, which encompasses Process Engineering, Discrete Manufacturing and Industrial Products. Through this alliance, LTTS will utilize the digital technology portfolio of Siemens Limited to deliver simulation-driven automation and IIoT-enabled solutions for diverse sectors including Automotive & Transportation, Industrial Products, and Process & Plant Engineering. By combining Siemens’ flagship platforms, TIA Portal, Industrial Edge, and Tec
SES Appoints Joseph Cohen to Board of Directors26.9.2025 08:50:00 CEST | Press release
With deep expertise in private equity, capital markets, and corporate finance, Joseph brings decades of financial leadership to the SES board SES today announced the appointment of Mr. Joseph Cohen, Co-Founding Partner of Trilantic Europe, to its Board of Directors effective immediately. This appointment is part of SES’s ongoing commitment to regularly review and strengthen the composition of its Board with diverse expertise and industry experience, ensuring the company is well positioned for future growth and value creation. Prior to his role as Co-Founding Partner of Trilantic Europe, Mr. Cohen spent over two decades at Lehman Brothers, including as European Co-Head of Lehman Brothers Merchant Banking and on the Investment Management Division’s European operating committee, among other roles. A U.K. citizen, he holds a BSc in Economics from the London School of Economics. Additionally, Mr. Kaj-Erik Relander has decided to step down from the SES Board of Directors, concluding a tenure
SES Confirms Interim Dividend of EUR 0.2526.9.2025 08:45:00 CEST | Press release
Interim dividend of EUR 0.25 per A-share approved as part of SES’s continued commitment to shareholder returns intended to be at least EUR 0.50 total dividend for FY2025 The SES Board of Directors has approved the payment of an interim dividend of EUR 0.25 per A-share (EUR 0.10 per B-share) to be paid to shareholders on October 16, 2025, in line with SES’s commitment to shareholder returns. The interim dividend to be paid in October 2025 will be followed, subject to financial results and shareholder approval, by the payment of a final dividend of at least EUR 0.25 per A-share (EUR 0.10 per B-share) in April 2026. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global ter
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom